Bruker Corporation (BRKR)

$56.22

+2.85

(+5.34%)▲

Market is closed - opens 8 PM, 22 Nov 2024

Performance

  • $52.59
    $56.34
    $56.22
    downward going graph

    6.46%

    Downside

    Day's Volatility :6.65%

    Upside

    0.2%

    downward going graph
  • $48.07
    $94.86
    $56.22
    downward going graph

    14.5%

    Downside

    52 Weeks Volatility :49.33%

    Upside

    40.73%

    downward going graph

Returns

PeriodBruker CorporationSector (Health Care)Index (Russel 2000)
3 Months
-11.74%
-6.9%
0.0%
6 Months
-28.19%
-1.7%
0.0%
1 Year
-13.57%
10.4%
0.0%
3 Years
-30.45%
8.8%
-24.1%

Highlights

Market Capitalization
8.1B
Book Value
$11.92
Dividend Share
0.2
Dividend Yield
0.41%
Earnings Per Share (EPS)
2.07
PE Ratio
25.78
PEG Ratio
3.64
Wall Street Target Price
74.737
Profit Margin
9.41%
Operating Margin TTM
10.0%
Return On Assets TTM
4.83%
Return On Equity TTM
19.73%
Revenue TTM
3.2B
Revenue Per Share TTM
21.98
Quarterly Revenue Growth YOY
16.400000000000002%
Gross Profit TTM
1.3B
EBITDA
551.9M
Diluted Eps TTM
2.07
Quarterly Earnings Growth YOY
-0.55
EPS Estimate Current Year
2.39
EPS Estimate Next Year
2.75
EPS Estimate Current Quarter
0.59
EPS Estimate Next Quarter
0.94

Analyst Recommendation

Buy
    66%Buy
    27%Hold
    5%Sell
Based on 18 Wall street analysts offering stock ratings for Bruker Corporation(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
5
5
6
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 32.94%

Current $56.22
Target $74.74

Company Financials

FY18Y/Y Change
Revenue
1.9B
↑ 7.34%
Net Income
179.7M
↑ 128.63%
Net Profit Margin
9.48%
↑ 5.03%
FY19Y/Y Change
Revenue
2.1B
↑ 9.34%
Net Income
197.2M
↑ 9.74%
Net Profit Margin
9.51%
↑ 0.03%
FY20Y/Y Change
Revenue
2.0B
↓ 4.11%
Net Income
157.8M
↓ 19.98%
Net Profit Margin
7.94%
↓ 1.57%
FY21Y/Y Change
Revenue
2.4B
↑ 21.66%
Net Income
277.1M
↑ 75.6%
Net Profit Margin
11.46%
↑ 3.52%
FY22Y/Y Change
Revenue
2.5B
↑ 4.67%
Net Income
296.6M
↑ 7.04%
Net Profit Margin
11.72%
↑ 0.26%
FY23Y/Y Change
Revenue
3.0B
↑ 17.14%
Net Income
427.2M
↑ 44.03%
Net Profit Margin
14.41%
↑ 2.69%
Q2 FY23Q/Q Change
Revenue
681.9M
↓ 0.5%
Net Income
57.1M
↓ 25.36%
Net Profit Margin
8.37%
↓ 2.79%
Q3 FY23Q/Q Change
Revenue
742.8M
↑ 8.93%
Net Income
88.1M
↑ 54.29%
Net Profit Margin
11.86%
↑ 3.49%
Q4 FY23Q/Q Change
Revenue
854.5M
↑ 15.04%
Net Income
205.5M
↑ 133.26%
Net Profit Margin
24.05%
↑ 12.19%
Q1 FY24Q/Q Change
Revenue
721.7M
↓ 15.54%
Net Income
50.9M
↓ 75.23%
Net Profit Margin
7.05%
↓ 17.0%
Q2 FY24Q/Q Change
Revenue
800.7M
↑ 10.95%
Net Income
7.6M
↓ 85.07%
Net Profit Margin
0.95%
↓ 6.1%
Q3 FY24Q/Q Change
Revenue
864.4M
↑ 7.96%
Net Income
40.9M
↑ 438.16%
Net Profit Margin
4.73%
↑ 3.78%
FY18Y/Y Change
Total Assets
2.1B
↑ 9.24%
Total Liabilities
1.2B
↑ 0.7%
FY19Y/Y Change
Total Assets
2.8B
↑ 30.2%
Total Liabilities
1.9B
↑ 51.57%
FY20Y/Y Change
Total Assets
3.0B
↑ 9.97%
Total Liabilities
2.1B
↑ 11.75%
FY21Y/Y Change
Total Assets
3.7B
↑ 19.75%
Total Liabilities
2.6B
↑ 23.79%
FY22Y/Y Change
Total Assets
3.6B
↓ 0.86%
Total Liabilities
2.5B
↓ 3.06%
FY23Y/Y Change
Total Assets
4.2B
↑ 17.45%
Total Liabilities
2.8B
↑ 14.07%
Q2 FY23Q/Q Change
Total Assets
3.9B
↑ 2.47%
Total Liabilities
2.6B
↑ 1.62%
Q3 FY23Q/Q Change
Total Assets
3.8B
↓ 1.01%
Total Liabilities
2.6B
↓ 0.79%
Q4 FY23Q/Q Change
Total Assets
4.2B
↑ 11.31%
Total Liabilities
2.8B
↑ 10.2%
Q1 FY24Q/Q Change
Total Assets
4.5B
↑ 6.04%
Total Liabilities
3.1B
↑ 7.72%
Q2 FY24Q/Q Change
Total Assets
5.9B
↑ 30.98%
Total Liabilities
4.1B
↑ 33.46%
Q3 FY24Q/Q Change
Total Assets
6.1B
↑ 3.56%
Total Liabilities
4.3B
↑ 4.7%
FY18Y/Y Change
Operating Cash Flow
239.7M
↑ 55.25%
Investing Cash Flow
-123.4M
↑ 308.61%
Financing Cash Flow
-112.4M
↓ 29.31%
FY19Y/Y Change
Operating Cash Flow
213.4M
↓ 10.97%
Investing Cash Flow
-158.4M
↑ 28.36%
Financing Cash Flow
300.0M
↓ 366.9%
FY20Y/Y Change
Operating Cash Flow
333.2M
↑ 56.14%
Investing Cash Flow
-192.7M
↑ 21.65%
Financing Cash Flow
-161.6M
↓ 153.87%
FY21Y/Y Change
Operating Cash Flow
282.4M
↓ 15.25%
Investing Cash Flow
-192.4M
↓ 0.16%
Financing Cash Flow
318.7M
↓ 297.22%
FY22Y/Y Change
Operating Cash Flow
262.0M
↓ 7.22%
Investing Cash Flow
-251.6M
↑ 30.77%
Financing Cash Flow
-415.2M
↓ 230.28%
Q2 FY23Q/Q Change
Operating Cash Flow
13.0M
↓ 85.14%
Investing Cash Flow
-26.0M
↓ 75.97%
Financing Cash Flow
-10.3M
↓ 66.45%

Technicals Summary

Sell

Neutral

Buy

Bruker Corporation is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bruker Corporation
Bruker Corporation
-7.07%
-28.19%
-13.57%
-30.45%
12.76%
Stryker Corporation
Stryker Corporation
6.59%
16.31%
32.68%
49.88%
93.53%
Boston Scientific Corp.
Boston Scientific Corp.
3.97%
21.4%
65.07%
124.82%
118.64%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
1.65%
-21.98%
4.95%
-38.71%
-12.32%
Abbott Laboratories
Abbott Laboratories
0.98%
11.87%
14.18%
-6.39%
40.03%
Medtronic Plc
Medtronic Plc
-7.0%
-1.19%
8.13%
-27.5%
-23.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bruker Corporation
Bruker Corporation
25.78
25.78
3.64
2.39
0.2
0.05
0.0
11.92
Stryker Corporation
Stryker Corporation
41.34
41.34
2.69
12.05
0.19
0.07
0.01
52.86
Boston Scientific Corp.
Boston Scientific Corp.
74.52
74.52
1.64
2.46
0.09
0.05
NA
14.05
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
27.17
27.17
6.38
2.53
0.19
0.11
NA
16.18
Abbott Laboratories
Abbott Laboratories
35.56
35.56
2.25
4.68
0.15
0.06
0.02
22.94
Medtronic Plc
Medtronic Plc
29.55
29.55
1.63
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bruker Corporation
Bruker Corporation
Buy
$8.1B
12.76%
25.78
9.41%
Stryker Corporation
Stryker Corporation
Buy
$147.0B
93.53%
41.34
16.34%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$132.9B
118.64%
74.52
11.26%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$41.5B
-12.32%
27.17
65.86%
Abbott Laboratories
Abbott Laboratories
Buy
$203.2B
40.03%
35.56
13.99%
Medtronic Plc
Medtronic Plc
Buy
$110.3B
-23.53%
29.55
12.06%

Insights on Bruker Corporation

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 721.7M → 864.4M (in $), with an average increase of 8.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 7.6M → 40.9M (in $), with an average increase of 81.4% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 65.1% return, outperforming this stock by 78.7%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 124.8% return, outperforming this stock by 155.2%

Institutional Holdings

  • FMR Inc

    9.44%

  • T. Rowe Price Investment Management,Inc.

    8.60%

  • Vanguard Group Inc

    7.06%

  • BlackRock Inc

    6.49%

  • Pallas Capital Advisors LLC

    6.25%

  • Massachusetts Financial Services Company

    3.60%

Corporate Announcements

  • Bruker Corporation Dividends March,2024

    In the quarter ending March,2024. Bruker Corporation has declared dividend of $0.05

    Read More

Company Information

right from the beginning, which is now more than fifty years ago, bruker has been driven by a single idea: to provide the best technological solution for each analytical task. today, worldwide, more than 6,500 employees in over 90 locations on all continents are focusing their efforts on this permanent challenge. bruker systems cover a broad spectrum of applications in all fields of research and development and are used in all industrial production processes for the purpose of ensuring quality and process reliability. bruker continues to build upon its extensive range of products and solutions, expand its broad base of installed systems and maintain a strong reputation amongst its customers. as one of the world's leading analytical instrumentation companies, bruker remains focused on developing state-of-the-art technologies and innovative solutions for today’s ever complex analytical questions. bruker - innovation with integrity. bruker corporation company pages bruker axs: https://www

Organization
Bruker Corporation
Employees
9707
CEO
Dr. Frank H. Laukien Ph.D.
Industry
Health Technology

FAQs